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ABSTRACT The firefly luciferase enzyme from Photinus pyralis is probably the best-characterized model system for
studying anesthetic-protein interactions. It binds a diverse range of general anesthetics over a large potency range, displays
a sensitivity to anesthetics that is very similar to that found in animals, and has an anesthetic sensitivity that can be modulated
by one of its substrates (ATP). In this paper we describe the properties of bromoform acting as a general anesthetic (in Rana
temporaria tadpoles) and as an inhibitor of the firefly luciferase enzyme at high and low ATP concentrations. In addition, we
describe the crystal structure of the low-ATP form of the luciferase enzyme in the presence of bromoform at 2.2-Å resolution.
These results provide a structural basis for understanding the anesthetic inhibition of the enzyme, as well as an explanation
for the ATP modulation of its anesthetic sensitivity.
INTRODUCTION
Despite a growing appreciation that the effects of general
anesthetics can be accounted for in terms of their direct
interactions with proteins (Forman et al., 1995; Franks and
Lieb, 1982, 1994; Mihic et al., 1997), there is remarkably
little information available on the nature or molecular ar-
chitectures of their binding sites (see Miller (1985) for a
review). Some information has been gleaned from correla-
tions of anesthetic potency with partitioning into defined
solvents (Abraham et al., 1991; Franks and Lieb, 1978;
Hansch et al., 1975; Taheri et al., 1991); however, this is an
approach that can only give a picture of an “average”
anesthetic-binding environment. What has emerged from
these studies is a site that is predominantly hydrophobic, or
apolar, but with a distinct polar component. The polar
aspect of anesthetic binding sites has been stressed by
several workers (Abraham et al., 1991; Franks and Lieb,
1978; Sandorfy, 1978), with an additional recent refinement
that this polar component appears to act as a good hydrogen
bond acceptor, but a poor donor (Abraham et al., 1991).
Apart from the pioneering studies of Schoenborn and his
colleagues on the binding of anesthetics to hemoglobin and
myoglobin (Schoenborn, 1976; Schoenborn et al., 1965),
detailed structural information on anesthetic-protein inter-
actions has been lacking; this information can only be
provided by techniques such as x-ray crystallography.
Recently in this laboratory we have determined (Conti et
al., 1996a) the crystal structure of what is probably the
best-characterized model of an anesthetic target, the firefly
luciferase enzyme. This soluble enzyme has been shown to
be inhibited by a diverse range of general anesthetics with a
sensitivity that closely parallels anesthetic potencies in an-
imals over five orders of magnitude (Franks and Lieb,
1984). In addition, the circumscribed dimensions and am-
phiphilic nature of the anesthetic-binding site on the lucif-
erase enzyme provide a plausible explanation (Franks and
Lieb, 1985) for the abrupt “cutoff” in potency that is found
in homologous series of long-chain compounds. Further-
more, the observation that high concentrations of one of its
substrates (ATP) trigger a conformational change in the
enzyme that enhances anesthetic binding (Moss et al., 1991)
provides added interest in the structure. This is because an
analogous behavior is found with several ion channel re-
ceptors, such as the GABAA, glycine, and 5-HT3 receptors.
With these ligand-gated ion channels, volatile anesthetics
enhance the apparent binding of the neurotransmitter,
which, as we have recently pointed out (Tomlin et al.,
1998), means that high concentrations of neurotransmitter
must in turn enhance the binding of anesthetics.
For all of these reasons, the high-resolution structure of
the firefly luciferase enzyme in the presence and absence of
general anesthetics is of considerable interest. In this paper
we report our first results using the simple achiral anesthetic
bromoform binding to the enzyme in the absence of ATP,
and we correlate our crystallographic analysis of the struc-
ture with the effects of bromoform on the activity of the
enzyme and as a general anesthetic in animals.
MATERIALS AND METHODS
Anesthetic potency measurements in tadpoles
The general anesthetic potency of bromoform was determined for 4–6-
week-old Rana temporaria tadpoles (Blades Biological Ltd., Cowden,
Kent, England) in the pre-limb-bud stage of development (average length
2 cm). Tadpoles were maintained in an aerated aquarium at 20–22°C.
During randomized blind anesthetic potency experiments, 10 tadpoles were
placed in each of a number of beakers containing 300 ml of tap water (20
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1°C), with or without bromoform. The anesthetic end point was defined as
the lack of a purposeful and sustained swimming response after a gentle
inversion with a smooth glass rod. The number of anesthetized tadpoles
was recorded every 10 min for 120 min (equilibrium was complete at
10–20 min), after which the tadpoles were returned to fresh tap water,
where recovery was monitored. In all cases, normal swimming activity was
restored within 30 min. Tadpole concentration-response data were fitted
according to the method of Waud (1972) to a logistic equation of the form
p
100I n
I n EC50n
(1)
where p is the percentage of the population anesthetized, I is the bromo-
form concentration, n is the slope, and EC50 is the bromoform concentra-
tion for a half-maximum effect.
Anesthetic inhibition measurements of
firefly luciferase
The luciferase enzyme from the North American firefly Photinus pyralis
was obtained from Promega (Southampton, England) as a 61-kDa recom-
binant monomeric protein. HEPPS (N-(2-hydroxyethyl)-piperazine-N-(3-
propanesulfonic acid)) and ATP (disodium salt, grade I) were purchased
from Sigma Chemical Company (Poole, Dorset, England), and D-luciferin
was obtained from Europa Research Products (Ely, Cambridgeshire, En-
gland). MgSO4 (Analar grade) was obtained from BDH (Poole, Dorset,
England), and bromoform was from either Sigma Chemical Company or
BDH.
Firefly luciferase combines with its substrate luciferin in the presence of
ATP, Mg2, and O2 to give a photon of light (McElroy and Seliger, 1961).
Luciferase activity and its inhibition by bromoform were determined
(Franks and Lieb, 1984) from the peak light output observed after 2.5 ml
of a buffered ATP solution was rapidly injected into a reaction vial
containing 5 ml of a buffered solution containing the luciferase enzyme, its
natural substrate firefly luciferin, MgSO4, and anesthetic (when appropri-
ate). See Dickinson et al. (1993) for further details. The buffer was 25 mM
HEPPS, titrated to pH 7.8 at 20°C with NaOH. Final concentrations were
2 mM or 2 M ATP, 6.67 mM MgSO4, 2–1800 M luciferin, and 3 nM
luciferase. Bromoform was added to the reaction vial in aliquots of a
saturated aqueous solution (taken to be 11.9 mM; IARC, 1991).
Enzyme inhibition is expressed as the ratio of the control peak height vo
to the peak height in the presence of anesthetic v and plotted as a function
of the anesthetic concentration I. Curves were fitted through these data
using the method of weighted least squares, with weights (derived by
assuming a constant percentage error in the measurement of enzyme
activity) proportional to (v/vo)2. When the data are plotted as v0/v,
straight lines were fitted with weights proportional to v/vo.
X-ray crystallography
Crystals of recombinant firefly luciferase belonging to space group P41212
with cell dimensions a 	 b 	 119.6 Å, c 	 95.8 Å, were obtained as
previously described (Conti et al., 1996b), using the microbatch technique.
The crystals were harvested and soaked for 5 min in a solution containing
16% w/v PEG 8000, 5% glycerol, 12.5% ethylene glycol, 100 mM Li2SO4,
and 60 mM Tris HCl (pH 7.8) with saturating bromoform and then
transferred and soaked for 2 min in a cryoprotectant solution, also saturated
with bromoform containing 8% w/v PEG 8000, 10% glycerol, 12.5%
ethylene glycol, and 100 mM Tris HCl (pH 7.8). Crystals were frozen in a
stream of nitrogen gas at 100 K, and diffraction data to 2.2-Å resolution
were recorded on a MarResearch (Hamburg, Germany) image plate detec-
tor using radiation produced by the synchrotron radiation source at Dares-
bury (England). The images were evaluated with the program MOSFLM
(Andrew Leslie, unpublished), and the data were reduced using the CCP4
program suite (CCP4, 1994). Starting with the coordinates obtained for the
unliganded luciferase molecule (Conti et al., 1996a), the structure was
refined with the program X-plor (Bru¨nger et al., 1987). Details of the data
collection and refinement are presented in Table 1. The coordinates have
been deposited with the Protein Data Bank (accession identifier: 1BA3).
RESULTS
We determined the potency of bromoform for producing a
loss of righting reflex in tadpoles (Rana temporaria). We
found that concentrations of bromoform in excess of 100
M rapidly (15 min) induced a reversible state of loss of
righting reflex and that the concentration-response curve
could be fitted by a logistic equation (see Materials and
Methods, Eq. 1) with an EC50 of 185  3 M bromoform
and a slope n 	 8.2  0.5 (see Fig. 1).
We studied the effects of bromoform on the firefly lucif-
erase enzyme at both high (2 mM) and low (2 M) con-
centrations of ATP because we (Moss et al., 1991) have
previously found that ATP can modulate the anesthetic
sensitivity of the enzyme, with luciferase being more sen-
sitive at high ATP concentrations. We found a similar
behavior here, with the peak light output being more sen-
sitive to bromoform at the higher ATP concentration (see
Fig. 2, A and B). In both cases, however, the inhibition
increased quadratically and v0/v increased linearly with
bromoform concentration, indicating that two molecules of
the anesthetic were involved in the inhibition of the enzyme.
We investigated the mechanism of bromoform inhibition
at low concentrations of ATP and found it to be largely
competitive (with respect to the substrate luciferin) in na-
ture. This can be seen from the double-reciprocal plot of
activity versus luciferin concentration in Fig. 3, which
shows that the control and inhibited lines come close to
intersecting on the ordinate axis (Fig. 3, dashed line) but
have very different intersections on the abscissa axis. Even
at the high concentration of 1600 M bromoform, the effect
on the maximum rate of the reaction Vmax was small (23%
TABLE 1 Crystallographic statistics
Synchrotron Daresbury
Beam line SRS 9.5
Wavelength 0.87 Å
Resolution range 18.4–2.2 Å
Measured reflections 109,681
Unique reflections 35,038
Rmerge* 7.1 (23.5)%#
Completeness 98.2 (97.9)%#
Refinement
Rfactor§ 19.7%
Rfree¶ 23.9%
Rms deviation from ideal bond lengths 0.007 Å
Rms deviation from ideal bond angles 1.51°
*Rmerge 	 100 
 ¥h ¥jIhj  Ih/¥h ¥jIhj, where Ih is the weighted mean
intensity of the symmetry related reflections Ihj.
#Values for the outermost resolution shell are given in parentheses.
§Rfactor 	 100 
 ¥Fobs  Fcalc/¥Fobs, where Fobs and Fcalc are the
observed and calculated structure factors, respectively.
¶Rfree is the Rfactor calculated using a random 5% sample of reflection data
omitted from refinement (Bru¨nger, 1992).
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reduction), with the predominant effect being an increase in
the apparent Michaelis constant Km (from 180  6 M to
460  30 M luciferin). Although the noncompetitive
element of the inhibition was small, we went on to charac-
terize it in more detail by measuring the inhibition of the
enzyme by bromoform at a concentration of luciferin that is
large (1800 M) compared to the luciferin Km (180 M at
an ATP concentration of 2 M). These data are shown in
Fig. 4, where they are compared to the inhibition observed
at a concentration of luciferin that is small (2 M) com-
pared to the luciferin Km. It can be seen that the inhibition
is greatly reduced and increases approximately linearly,
rather than quadratically, when the luciferin concentration is
increased from 2 to 1800 M.
We determined the high-resolution structure of the lucif-
erase enzyme in the presence of saturating concentrations of
bromoform, but in the absence of ATP (despite extensive
crystallization trials, we have been unable to obtain crystals
of luciferase in its “high-ATP” form). From the x-ray dif-
fraction data we calculated a difference electron density
map (i.e., with and without bromoform) that clearly re-
vealed the positions of two bromoform molecules binding to
the enzyme (and three short loops of the polypeptide chain
that had previously been omitted from the original struc-
ture). There was no evidence for any other bromoform-
binding site. The final model included residues 3–198 and
201–544 and 351 water molecules (see Table 1 for the
crystallographic statistics).
An overview of the structure is shown in Fig. 5 A. As
previously described (Conti et al., 1996a), the enzyme con-
sists of two domains: a large N-terminal domain and a
smaller C-terminal domain that we believe move together to
sandwich the luciferin and ATP substrates when they bind
to the enzyme (we refer to the two conformations as the
“low-ATP” and “high-ATP” forms of the structure). The
two bromoform molecules lie close to one another and bind
within pockets in the large N-terminal domain, causing
minimal perturbations to the overall structure. A more de-
tailed view of the binding environments is shown by the
stereo representation in Fig. 5 C. One of the two anesthetic
molecules is bound in a pocket that we can identify as the
luciferin substrate-binding site (see Discussion), whereas
the other is bound to a pocket accessible from the external
surface of the enzyme and abuts the luciferin pocket. The
binding environment of the bromoform molecule in the
FIGURE 1 Concentration-response data for loss of righting reflex in
tadpoles (Rana temporaria) for bromoform. Each data point (F) represents
the mean response for an average of nine tadpoles. The line is a best fit to
a logistic function defined by Waud (1972) for the analysis of quantal
concentration-response curves (see Materials and Methods, Eq. 1). The
error bars are standard errors of the mean. Where error bars are not shown
they are smaller than the symbol. The best fit gave EC50 	 185  3 M
and slope n 	 8.2  0.5. Note that the abscissa is on a logarithmic scale.
FIGURE 2 Inhibition of the firefly luciferase enzyme involves two mol-
ecules of bromoform. (A) Inhibition at high (2 mM) ATP. (B) Inhibition at
low (2 M) ATP. In both cases the luciferin concentration was 2 M.
Enzyme inhibition is expressed as a ratio of the control to the inhibited
response (F) and as a square root of this ratio (E). Each data point
represents the mean of at least three determinations; the error bars are
standard errors of the mean. Where error bars are not shown they are
smaller than the symbol. The lines are weighted (see Materials and Meth-
ods) least-squares fits to the data, constrained to go through unity on the
ordinate axis. The ratio vo/v is fit to a quadratic equation, whereas v0/v
is fit by a straight line. The insets show typical control and inhibited flashes
with 160 M bromoform for (A) and 800 M bromoform for (B).
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luciferin pocket is amphiphilic in nature, with one side of
the anesthetic in close contact with apolar glycine and
alanine residues (315 and 313, respectively), whereas the
other side is coordinated by water molecules and two polar
side chains: Arg218 and Glu311. It also interacts with the
aliphatic chain of Arg337, which forms the “base” of the
luciferin pocket. The bromoform in the “external” site is in
a remarkably polar environment and makes specific inter-
actions with two glutamic acids (311 and 354), Thr352,
His310, and the guanidinium group of Arg337. Although the
overall structure of the N-terminal domain was little af-
fected on anesthetic binding (the C carbon atoms could be
superposed to give an rms difference of 0.21 Å), there were
small realignments of some of the amino acid side chains
that were in contact with the bromoform molecules. His310
was disordered in the original structure, but the presence of
a bromoform molecule has provided a sufficiently strong
interaction so that clear density for the histidine side chain
appeared when the anesthetic molecules bound. Similarly,
the carboxylate moieties of the two glutamic acid side
chains (311 and 354) both move slightly to coordinate the
bromoform molecules. The only other change in the enzyme
structure on anesthetic binding is a conformational change
in the aliphatic chain of Arg337, although the guanidinium
group itself remains in a similar position.
DISCUSSION
Although it is known that bromoform has sedative proper-
ties (IARC, 1991), its anesthetic potency has not, to our
knowledge, been determined. Its EC50 concentration of 185
M for inducing a loss of righting reflex in tadpoles (Fig. 1)
is close to that which could have been predicted from its
physical properties (octanol/water partition coefficient log10
Poct 	 2.38, aqueous solubility Csat 	 11.9 mM, IARC
(1991)), or its ability to inhibit the high-ATP form of the
firefly luciferase enzyme (see Fig. 2 A). By these measures
it can therefore be considered to be an unexceptional gen-
eral anesthetic and has an anesthetic potency and physical
properties similar to those of the inhalational agent halo-
thane (log10 Poct 	 2.30; Csat 	 17.5 mM, and tadpole
EC50 	 230 M; Firestone et al., 1986; Ravento´s, 1956).
The inhibition of the firefly luciferase enzyme by bromo-
form also followed a familiar pattern (Franks and Lieb,
1984), with two molecules of the anesthetic being involved
in the inhibition, and this inhibition being greater at high,
rather than low, concentrations (Moss et al., 1991) of the
substrate ATP (see Fig. 2). Because we could only obtain
crystals of the enzyme in the absence of ATP, we mainly
studied the effects of bromoform on enzyme activity at a
very low ATP concentration (2 M). Under these condi-
tions, the inhibition was predominantly competitive (Fig. 3),
although there was also a small degree of noncompetitive
inhibition. This was made more apparent when the inhibi-
tion was measured with the luciferin binding site effectively
saturated (by using a luciferin concentration 10 times
greater than its Km). This showed that a single, relatively
weakly binding, bromoform molecule was responsible for
the noncompetitive component, because with the luciferin
site saturated, the inhibition increased roughly linearly with
bromoform concentration (Fig. 4).
FIGURE 3 Anesthetic inhibition of firefly luciferase at a low ATP
concentration (2 M) is largely competitive with respect to luciferin. The
reciprocal of the luciferase activity is plotted against the reciprocal of the
luciferin concentration: F, control; E, 1600 M bromoform. Each data
point represents the mean of at least three determinations, and the error bars
are standard errors of the mean. Where error bars are not shown they are
smaller than the symbol. The straight lines were calculated using the
method of weighted least squares (see Materials and Methods). For the
control, Km 	 180  6 M luciferin and Vmax 	 100  0.5. In the
presence of 1600 M bromoform, the apparent Km 	 460  30 M
luciferin and Vmax 	 77  3.
FIGURE 4 The inhibition observed when the luciferin concentration is
small (2 M) compared to the luciferin Km (180 M) increases quadrati-
cally, whereas the inhibition is greatly reduced and increases approxi-
mately linearly when the luciferin concentration is large (1800 M) com-
pared to the luciferin Km. In both cases the ATP concentration was 2 M.
The lines are calculated using the model described in the discussion. See
text for details.
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Therefore, the simplest model that fits our inhibition data
is one in which there is a single, relatively high-affinity site
to which bromoform binds in competition with the luciferin
substrate, and a weaker noncompetitive site that binds in-
dependently of the luciferin concentration. An equilibrium
scheme describing this model is shown below:
where the luciferase enzyme E, luciferin substrate S, and
bromoform inhibitors I are shown at equilibrium with their
various complexes; KS is the luciferin dissociation constant;
Ki is the dissociation constant for the competitive bromo-
form molecule; and Ki is the dissociation constant for the
noncompetitive bromoform molecule.
It is straightforward to show that, according to this
scheme, the rate of the luciferase reaction v is given by
 
VmaxS
S KS1 IKi1 IKi
(2)
where Vmax is the maximum rate of the reaction and S is the
luciferin concentration. Hence the ratio of rates in the ab-
sence (vo) and presence (v) of bromoform is given by
v0
v S, I
S KS1 IKi1 IKi
S KS
(3)
When this equation is fitted to the data of Fig. 4 with both
S and I as independent variables, excellent agreement is
obtained, with this simple model accounting for the data at
both high and low luciferin concentrations. The best fit to
the data gives values for the competitive and noncompeti-
tive dissociation constants of 790 30 M and 5800 400
M, respectively.
What are the molecular architectures of these anesthetic
binding sites? The crystal structure that we have determined
was under conditions that would have strongly favored the
IEI complex in the above scheme. The two bromoform
molecules were immediately apparent in the structure, with
unambiguous and well-defined electron densities (Fig. 5 C).
The anesthetic molecules evidently bind to the enzyme in
preformed pockets, much as we had anticipated some years
ago (Franks and Lieb, 1984, 1985). There is no generalized
or even local disordering of the structure. Indeed, the only
small rearrangements are local ordering or slight realign-
ments of certain amino acid residues. The old suggestion
(Ueda and Kamaya, 1973) that general anesthetics inhibit
the firefly luciferase enzyme by disordering its structure is
clearly incorrect.
One of the two bromoform molecules can be readily
identified as the competitive inhibitor (magenta in Fig. 5)
because it binds in a pocket on the enzyme that has been
tentatively identified as the luciferin-binding site by analogy
with the substrate-binding site on the structurally related
enzyme, gramicidin synthetase (Conti et al., 1997). This
bromoform molecule binds within a cavity that has both
polar and apolar characteristics, with water and polar resi-
dues on one side and apolar residues on the other. Although
we expected to see anesthetic molecules binding to an
amphiphilic pocket on the protein (Franks and Lieb, 1985),
and anticipated that this would also form a part of the
luciferin-binding site (Moss et al., 1991), we did not expect
to see an additional, and strikingly polar, anesthetic-binding
pocket (containing the yellow bromoform molecule in Fig.
5, A and C). This binding site presumably accounts for the
weak noncompetitive component of the inhibition. Al-
though this site only provides a relatively weak binding
environment for bromoform, it does show that polar inter-
actions can orient and order anesthetic molecules with large
polarizable atoms such as bromine. This has previously
been observed for the binding of dichloroethane to insulin
(Gursky et al., 1994).
The structure we have determined is the “low-ATP” form
of the enzyme that binds anesthetics, including bromoform,
less tightly than the “high-ATP” form (see Fig. 2 and Moss
et al., 1991). What can be learned from our structure about
the molecular basis for this changing anesthetic affinity?
Until we have determined the luciferase structure in its
“high-ATP” form, we cannot draw definitive conclusions;
nonetheless, a great deal can be inferred from a comparison
with gramicidin synthetase, the structure of which has been
determined in its “high-ATP” form (Conti et al., 1997). This
enzyme catalyzes a reaction analogous to that of firefly
luciferase, except that the firefly luciferin substrate is re-
placed by phenylalanine, and a phenylalanine-AMP adenyl-
ate is formed, rather than a luciferyl-AMP adenylate. De-
spite a sequence identity of only 16% (Conti et al., 1997),
the two enzymes are closely related structurally, with N-
and C-terminal domains of similar topologies in the two
proteins, and with domain structures that superimpose with
an rms deviation of the main-chain -carbon atoms of less
than 1.5 Å (for all atoms within 3 Å). The main difference
between the structures is that the gramicidin synthetase
enzyme was crystallized in the presence of ATP and the N-
and C-terminal domains have come together, sandwiching
the substrates.
A comparison between the “low-ATP” luciferase struc-
ture and the “high-ATP” gramicidin synthetase structure
shows that, in addition to the relative movement of the N-
and C-terminal domains, a loop of main chain (residues
314–319) moves several Ångstroms on ATP binding (see
Fig. 5 B). In the low-ATP structure this loop hinders sub-
strate (luciferin or phenylalanine) binding by constricting
one dimension of the binding pocket. However, in the
high-ATP structure, the loop has moved so as to form a
cavity large enough to bind the substrate. We can therefore
suppose that this will also provide space for the binding of
a second competitive anesthetic molecule. Interestingly,
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with halothane, two molecules bind to the luciferase enzyme
in its high-ATP form, whereas only a single molecule binds
at low ATP, an observation entirely consistent with this
picture (Moss et al., 1991).
However, the binding of a second competitive molecule
with the same affinity as the first is not sufficient to explain
the enhanced anesthetic sensitivity at high ATP concentra-
tions. In the case of bromoform, the two competitive mol-
ecules in the high-ATP form would have to bind signifi-
cantly more tightly than the single competitive molecule in
the low-ATP form to account for the increased inhibition
observed at high ATP concentrations. An explanation for
the enhanced anesthetic sensitivity is likely to lie in the fact
that, when ATP binds to the enzyme and the two domains of
the protein come together, the anesthetic molecules binding
within the luciferin-binding pocket are trapped, effectively
enhancing their apparent binding affinities. The same mech-
anism would also account for the increased affinity of
luciferin observed at high concentrations of ATP (Moss et
al., 1991).
FIGURE 5 Two molecules of bromoform bind to the luciferase enzyme. (A) Ribbon representation of the firefly luciferase molecule showing the large
N-terminal domain (residues 4–437) in green and the smaller C-terminal domain (residues 438–544) in blue. The bromoform molecule that binds in the
luciferin-binding pocket is shown in magenta, and the bromoform molecule that binds to an “external” polar pocket is shown in yellow. (B) The structural
basis for the enhanced anesthetic sensitivity of the luciferase enzyme at high ATP concentrations. The diagram compares the conformation of the
polypeptide backbone of the “low-ATP” firefly luciferase structure (green) with that of gramicidin synthetase (red), which was cocrystallized in the
presence of high concentrations of ATP (Conti et al., 1997). The position of the competitive bromoform molecule (shown in magenta) in the firefly
luciferase binding pocket (gray shading) is illustrated. The diagram shows the position of the substrate firefly luciferin deduced from the position of its
analogous substrate (phenylalanine) in the crystal structure of gramicidin synthetase. (C) Stereo diagram showing the amino acid residues of firefly
luciferase that are within 4 Å of the two bound bromoform molecules. The water molecules are shown as isolated red spheres. The bromoform molecules
are each contained within defined pockets or cavities in the protein. The diagram includes difference electron density (in blue) contoured at 4 with the
anesthetic molecules omitted from the model. The figure was generated using Raster3D (Merritt and Bacon, 1997) and Molscript (Kraulis, 1991), with
modifications by R. Esnouf (1997).
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Although the structure of the high-ATP form of the
luciferase enzyme will be needed before we can confidently
explain its remarkable ability to bind such a diverse range of
general anesthetics, certain clear conclusions can be drawn
from the present study. Anesthetics exert their effects by
binding to preformed pockets on the protein with minimal
perturbations to the overall structure. The main anesthetic-
binding site that accounts for the inhibition is the luciferin-
binding pocket itself, and the competitive nature of the
inhibition has a straightforward molecular explanation. This
binding site is amphiphillic, with both polar and apolar
characteristics. When ATP binds to the enzyme, the lucife-
rin-binding site increases in size, and its exit becomes
occluded. This provides a explanation for the enhanced
anesthetic binding at high ATP concentrations.
We thank the Medical Research Council (UK) for support.
REFERENCES
Abraham, M. H., W. R. Lieb, and N. P. Franks. 1991. Role of hydrogen
bonding in general anesthesia. J. Pharm. Sci. 80:719–724.
Bru¨nger, A. T. 1992. The free R value: a novel statistical quantity for
assessing the accuracy of crystal structures. Nature. 355:472–474.
Bru¨nger, A. T., J. Kuriyan, and M. Karplus. 1987. Crystallographic R-
factor refinement by molecular-dynamics. Science. 235:458–460.
CCP4. 1994. The CCP4 suite: programs for protein crystallography. Acta
Crystallogr. D. 50:760–767.
Conti, E., N. P. Franks, and P. Brick. 1996a. Crystal structure of firefly
luciferase throws light on a superfamily of adenylate-forming enzymes.
Structure. 4:287–298.
Conti, E., L. F. Lloyd, J. Akins, N. P. Franks, and P. Brick. 1996b.
Crystallization and preliminary diffraction studies of firefly luciferase
from Photinus pyralis. Acta Crystallogr. D. 52:876–878.
Conti, E., T. Stachelhaus, M. A. Marahiel, and P. Brick. 1997. Structural
basis for the activation of phenylalanine in the non-ribosomal biosyn-
thesis of gramicidin S. EMBO J. 16:4174–4183.
Dickinson, R., N. P. Franks, and W. R. Lieb. 1993. Thermodynamics of
anesthetic/protein interactions. Temperature studies on firefly luciferase.
Biophys. J. 64:1264–1271.
Esnouf, R. M. 1997. An extensively modified version of Molscript that
includes greatly enhanced coloring capabilities. J. Mol. Graph. 15:
133–138.
Firestone, L. L., J. C. Miller, and K. W. Miller. 1986. Tables of physical
and pharmacological properties of anesthetics. InMolecular and Cellular
Mechanisms of Anesthetics. S. H. Roth and K. W. Miller, editors.
Plenum, New York. 455–470.
Forman, S. A., K. W. Miller, and G. Yellen. 1995. A discrete site for
general anesthetics on a postsynaptic receptor. Mol. Pharmacol. 48:
574–581.
Franks, N. P., and W. R. Lieb. 1978. Where do general anaesthetics act?
Nature. 274:339–342.
Franks, N. P., and W. R. Lieb. 1982. Molecular mechanisms of general
anaesthesia. Nature. 300:487–493.
Franks, N. P., and W. R. Lieb. 1984. Do general anaesthetics act by
competitive binding to specific receptors? Nature. 310:599–601.
Franks, N. P., and W. R. Lieb. 1985. Mapping of general anaesthetic target
sites provides a molecular basis for cutoff effects. Nature. 316:349–351.
Franks, N. P., and W. R. Lieb. 1994. Molecular and cellular mechanisms
of general anaesthesia. Nature. 367:607–614.
Gursky, O., E. Fontano, B. Bhyravbhatla, and D. L. D. Caspar. 1994.
Stereospecific dihaloalkane binding in a pH-sensitive cavity in cubic
insulin crystals. Proc. Natl. Acad. Sci. USA. 91:12388–12392.
Hansch, C., A. Vittoria, C. Silipo, and P. Y. C. Jow. 1975. Partition
coefficients and the structure-activity relationship of the anesthetic
gases. J. Med. Chem. 18:546–548.
IARC. 1991. IARC Monogr. Eval. Carcinog. Risks Hum. 52:213–242.
Kraulis, P. J. 1991. MOLSCRIPT: a program to produce both detailed and
schematic plots of protein structures. J. Appl. Crystallogr. 24:946–950.
McElroy, W. D., and H. H. Seliger. 1961. Mechanisms of bioluminescent
reactions. In Light and Life. W. D. McElroy and B. Glass, editors. The
Johns Hopkins University Press, Baltimore. 219–257.
Merritt, E. A., and D. J. Bacon. 1997. Raster3D: photorealistic molecular
graphics. Methods Enzymol. 227:505–524.
Mihic, S. J., Q. Ye, M. J. Wick, V. V. Koltchine, M. D. Krasowski, S. E.
Finn, M. P. Mascia, C. F. Valenzuela, K. K. Hanson, E. P. Greenblatt,
R. A. Harris, and N. L. Harrison. 1997. Sites of alcohol and volatile
anaesthetic action on GABAA and glycine receptors. Nature. 389:
385–389.
Miller, K. W. 1985. The nature of the site of general anesthesia. Int. Rev.
Neurobiol. 27:1–61.
Moss, G. W. J., N. P. Franks, and W. R. Lieb. 1991. Modulation of the
general anesthetic sensitivity of a protein: a transition between two
forms of firefly luciferase. Proc. Natl. Acad. Sci. USA. 88:134–138.
Ravento´s, J. 1956. The action of fluothane—a new volatile anaesthetic.
Br. J. Pharmacol. Chemother. 11:394–410.
Sandorfy, C. 1978. Intermolecular interactions and anesthesia. Anesthesi-
ology. 48:357–359.
Schoenborn, B. P. 1976. Dichloromethane as an antisickling agent in sickle
cell hemoglobin. Proc. Natl. Acad. Sci. USA. 73:4195–4199.
Schoenborn, B. P., H. C. Watson, and J. C. Kendrew. 1965. Binding of
xenon to sperm whale myoglobin. Nature. 207:28–30.
Taheri, S., M. J. Halsey, J. Liu, E. I. Eger, II, D. D. Koblin, and M. J.
Laster. 1991. What solvent best represents the site of action of inhaled
anesthetics in humans, rats, and dogs? Anesth. Analg. 72:627–634.
Tomlin, S. L., A. Jenkins, W. R. Lieb, and N. P. Franks. 1998. Stereose-
lective effects of etomidate optical isomers on gamma-aminobutyric acid
type A receptors and animals. Anesthesiology. 88:708–717.
Ueda, I., and H. Kamaya. 1973. Kinetic and thermodynamic aspects of the
mechanism of general anesthesia in a model system of firefly lumines-
cence in vitro. Anesthesiology. 38:425–436.
Waud, D. R. 1972. On biological assays involving quantal responses.
J. Pharmacol. Exp. Ther. 183:577–607.
Franks et al. Binding of Bromoform to Firefly Luciferase 2211
